Steven Horwitz

Steven Horwitz is one of the foremost clinical experts on T-cell lymphoma who led pivotal studies of romidepsin, pralatrexate, and mogamulizumab in peripheral T-cell lymphoma subtypes. He has a deep understanding of PTCL heterogeneity and the need for subtype-specific treatment strategies. His work at MSKCC encompasses both aggressive and indolent T-cell lymphomas and spans early-phase trials to outcomes analyses in real-world populations.